Replies to post #152129 on Biotech Values

[DewDiligence]

BMY’s 3-DAA cocktail shows 94% SVR12 for 12-week arm in treatment-naïve genotype-1 HCV:

http://finance.yahoo.com/news/investigational-triple-daa-regimen-daclatasvir-203000008.html

The three drugs in the cocktail are Daclatasvir (NS5A), Asunaprevir (PI), and BMS-791325 (non-nuke).

The 94% SVR12 rate in the 12-week arm was 15 of 16 patients. This trial also has a 24-week arm for which SVR12 data have not yet been reported, but SVR*4* was 94% (also 15 of 16).